LEQSELVI Shows Meaningful Hair Regrowth in Alopecia Areata by Week 8
At the AAD (American Academy of Dermatology) Annual Meeting in Denver, held March 27-31, 2026, a wave of data reshaped the conversation around hair loss treatment. Among the standout presentations, Sun Pharma’s LEQSELVI (deuruxolitinib) delivered phase 3 trial results showing significant scalp hair regrowth in alopecia areata patients, with effects visible as early as week 8 and sustained through week 12.
What Alopecia Areata Is, and Why It Has Been Hard to Treat
Alopecia areata is an autoimmune condition. The immune system misidentifies hair follicles as foreign tissue and attacks them. The pattern of hair loss ranges from coin-sized circular patches to complete scalp hair loss, and in severe cases extends to eyebrows, eyelashes, and body hair.
Standard treatment options, largely topical or injected corticosteroids, have long struggled to maintain long-term regrowth and carry high relapse rates. What patients needed was an oral therapy that could address the underlying immune response rather than its surface effects.
JAK Inhibitors Block the Signal
LEQSELVI belongs to a class called JAK inhibitors. JAK stands for Janus kinase, a molecular switch that immune cells use to transmit inflammatory signals. When those switches stay on too long, hair follicles come under sustained immune attack. LEQSELVI selectively blocks that signaling pathway, reducing the intensity of the immune assault on follicles.
The oral format matters practically: patients do not need clinic visits for administration. In the phase 3 trials, LEQSELVI-treated patients showed statistically significant scalp hair regrowth beginning at week 8, with results continuing through week 12. The data were presented at AAD 2026 by Sun Pharma.
A Completely Different Mechanism Also Made Its Debut
Another presentation at AAD 2026 introduced rezpegaldesleukin, a drug that works along an entirely different axis. Rather than blocking inflammatory signals, it stimulates regulatory T cells, the immune cells responsible for calming an overactive immune response. In alopecia areata, reduced regulatory T-cell activity is thought to allow immune attacks on follicles to go unchecked. The rezpegaldesleukin data were proof of concept rather than late-stage results, but they signal that the therapeutic toolkit for alopecia areata is broadening considerably.
Combination Protocols Are Gaining Ground
Beyond LEQSELVI, AAD 2026 featured Nutrafol Men 50+ as a case study in addressing multifactorial hair loss, where hormonal changes, nutritional gaps, stress, and chronic inflammation all contribute simultaneously. Single-ingredient approaches are giving way to formulas designed to address multiple root causes at once.
Combination protocols pairing oral and topical minoxidil with PRP (platelet-rich plasma), microneedling, and energy-based devices including LED and laser therapies were also widely presented. The logic is straightforward: results improve when treatments work together rather than in isolation.
Dermatology Is Shifting Toward Personalized, Long-Term Care
The overarching direction at AAD 2026 was personalization, prevention, and sustained outcomes. The standard of care is moving away from one-time interventions and toward treatment plans designed around individual physiology and long-term monitoring. Regenerative medicine and systemic longevity practices are crossing into dermatology faster than expected, according to assessments from the meeting.
LEQSELVI is the brand name for deuruxolitinib, developed by Sun Pharma and FDA-approved for severe alopecia areata in adults. Alopecia areata affects approximately 2% of the global population, and meaningful advances in this space have been limited for decades. The momentum coming out of AAD 2026 suggests that is changing.
Sources
NewBeauty, AAD 2026 Annual Meeting (March 27-31, Denver, Colorado), HCPLive